|Bid||0.0350 x 0|
|Ask||0.0500 x 0|
|Day's Range||0.0500 - 0.0500|
|52 Week Range||0.0150 - 0.5600|
|Beta (3Y Monthly)||1.68|
|PE Ratio (TTM)||0.94|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
VANCOUVER , June 1, 2018 /CNW/ - Winston Resources Inc. ("Winston" or the "Company") (CSE: WRW) (FSE:WNT) is pleased to announce that further to its news release on May 24, 2018 , the Company intends to complete the distribution (the "Distribution") of a total of 15,000,000 common shares (the "Abattis Shares") of Abattis Bioceuticals Corp. ("Abattis") on or about June 8, 2018 on a pro rata basis to the Company's shareholders of record as of January 23, 2018 (the "Winston Shareholders"). Each Winston Shareholder is entitled to receive approximately 0.5968 of one Abattis Share for each common share of Winston held.
FSE:WNT) is pleased to announce that further to its news release on January 11, 2018 that the Company intends to distribute the 15,000,000 common shares (the "Abattis Shares") of Abattis Bioceuticals Corp. ( "Abattis") on a pro rata basis to the holders of record as of January 23, 2018 (the "Winston Shareholders") of common shares of Winston (the "Proposed Distribution"). The Abattis Shares are subject to a hold period expiring May 25, 2018 . Winston acquired the Abbatis Shares pursuant to the terms of an assignment agreement dated January 10, 2018 (the "Assignment Agreement") between Winston and Abbatis relating to the acquisition of GT Therapeutics Corporation, dba Green Tree Therapeutics ("GTT"). In connection with the closing of the acquisition of GTT by Abattis on January 25, 2018 , the Company was issued the Abattis Shares.